This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Boston Scientific's (BSX) POLARx System Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
by Zacks Equity Research
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Pharma ETFs in Focus Post Q2 Earnings
by Sweta Killa
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
by Zacks Equity Research
Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.
Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk
by Kinjel Shah
Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
The Zacks Analyst Blog Highlights PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy
by Zacks Equity Research
PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy are included in this Analyst Blog.
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
by Zacks Equity Research
Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
by Zacks Equity Research
Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.
Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.
5 Defensive Stocks for Stable Returns Amid Recent Volatility
by Nalak Das
We have narrowed our search to five stocks from defensive sectors. These are: JNJ, PEP, ISRG, KMB, ATO.
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View
by Zacks Equity Research
Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.
CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.